Search Results
10
Everything
Search Filters
Tag
Covid-19
Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025
March 12, 2025 16:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., March 12, 2025 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (Nasdaq: DYAI), a biotechnology company focused on the efficient...
Callan JMB Awarded Second 5-Year Contract by the Oregon Health Authority for Emergency Preparedness and Response after Successful Operations for COVID-19 and MPOX Pandemics
February 11, 2025 09:00 ET
|
Callan JMB Inc.
During COVID, over 800,000 vaccines in Oregon were received, repackaged, and distributed covering over 75,000 miles SPRING BRANCH, Texas, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Callan JMB INC. (NASDAQ:...
Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19
January 27, 2025 06:30 ET
|
Ocugen
OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in 2Q...
AIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID Conditions
January 23, 2025 08:50 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Jan. 23, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the final Clinical Study Results for the “Study to Evaluate the...
AIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFS
January 22, 2025 08:30 ET
|
AIM ImmunoTech Inc.
Recently published article on study findings underscores links between study participants infected with SARS-CoV-2 and the incidence of ME/CFS The early-onset broad-spectrum antiviral effect of...
Most Americans Support Pandemic Policies but Have Concerns About Implementation
January 14, 2025 09:53 ET
|
de Beaumont Foundation
Bethesda, Maryland, Jan. 14, 2025 (GLOBE NEWSWIRE) -- As the U.S. faces continuing infectious disease outbreaks, a new study shows that a majority of Americans are likely to support mitigation...
BioNTech gibt auf der 43. J.P. Morgan Healthcare-Konferenz Updates zur Geschäfts- und Pipeline-Entwicklung
January 14, 2025 06:45 ET
|
BioNTech SE
BioNTech fokussiert sich in der Umsetzung der Onkologie-Strategie auf tumorübergreifende (Pan-Tumor-) Therapieansätze basierend auf Kombinationen mit BNT327/PM8002 sowie den...
BioNTech Provides Business and Pipeline Updates at 43rd Annual J.P. Morgan Healthcare Conference
January 14, 2025 06:45 ET
|
BioNTech SE
Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches BioNTech aims to develop BNT327/PM8002 as a...
AIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of Fatigue
December 12, 2024 09:00 ET
|
AIM ImmunoTech Inc.
OCALA, Fla., Dec. 12, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that the Netherlands Patent Office (Octrooicentrum Nederland) has...
COVID Non-pharmaceutical Interventions Were Harmful Authoritarian Overreach, according to Journal of American Physicians and Surgeons
December 10, 2024 10:02 ET
|
Association of American Physicians and Surgeons
Pandemic control measures for COVID likely did more damage than the disease itself. They were imposed without sound evidence, ignoring social consequences.